The export situation of API is depressed Industrial transformation and upgrading pressure is great.

Xinhua.com.au Data for January and February show that China's API exports have continued to be depressed since the fourth quarter of 2012, and are difficult to reverse in the short term. The task of industry transformation and upgrading is arduous, and the industry is feeling more and more pressure.
veS .Export growth continued to hover at a low
veS2013, is a rough year for the API industry, many problems are gradually emerging or getting worse during the year. According to data provided by the China Medical and Health Products Import and Export Chamber of Commerce (hereinafter referred to as the "Medical Insurance Chamber of Commerce"), China's exports of API were US$23.6 billion last year, up 2.6% YoY;
veS .In January and February this year, the situation continued last year, export growth rate is still hovering at a low level, export volume and export volume slightly increased, and export volume growth is smaller than the increase in export volume. In January-February, exports of API increased by 5% year-on-year to 1.03 million tons, while exports amounted to US$3.8 billion, up 3.9% YoY. Average unit prices for exports fell by 1.3% year-on-year.
veS .Bulk API belongs to the more mature products, the entry threshold is low, the technical and equipment requirements are simple, the production enterprises are very many, the competition is fierce. This kind of product has always been the most advantageous pharmaceutical export varieties in China. "But since the fourth quarter of 2012, exports of API, especially bulk API, have fallen sharply, with more than a dozen of the major API drugs exported in 2013 showing double-digit negative growth." Xu Ming, vice president of the Medical Insurance Chamber of Commerce, told reporters: "The bulk of API has entered the downward channel, in the short term it is difficult to reverse the trend." It's good to expect growth of 1% to 2% for the full year. "
veSin recent years, the export of specialty api, the profit margin of such products is relatively large, less domestic manufacturers. From January and February of this year, the market of specialty api, such as statins, anti-cancer drugs, etc. is good, Cao Gang, director of the Western Pharmaceutical Department of the Medical Insurance Chamber of Commerce, expects the annual growth rate of RAW drugs exports will remain at about 5%-8%.
veS .Ranking Merchandise Exports (US$10,000) Growth Export Price (USD/kg)
veS 1 Vitamin E 56,155 -13.32% 14.56
veS 2 Vitamin C 26,842 -2.48% 3.46
veS 3 tetracycline 16,472 -7.40% 24.67
Pine 13,132 19.47% 996.04
veS 5 Lincomycmycin 12,861 5.60% 113.35
veS 6 Coenzyme Q10 8,328 -24.87% 218.86
veS 7 vitamin B6 6,938 -7.59% 22.5
s . Vitamin B1 6,575 -13.10% 18.1
veS 9 Caffeine 6,417 -4.84% 8.4
veS 10 Vitamin B5 6,355 14.89% 7.64
veSmultiple reasons caused by the decline of RAW materials exports
Safter the previous two years of exports of RAW materials up to double-digit growth, the industry's export growth in the last two years is difficult.
veS .Industry analysis, there are mainly the following reasons: from the external market, foreign customers due to financial constraints to reduce inventory and procurement volume, more attention to prices, increased inquiries, large orders, long orders into small single; Even some enterprises lack of integrity, contract awareness is indifferent, and foreign customers to cooperate quickly and quickly, but also affected China's API products in the international market reputation and customer long-term cooperation.
veS .In addition, the fluctuation of RMB exchange rate also to a certain extent increases the difficulty of enterprise pricing, affecting enterprises to take orders. Although some companies require sales contracts at current exchange rates or rmb to settle in exchange rates in order to reduce the risk of fluctuations in the renminbi, customers generally do not agree to settle in renminbi for their own benefit.
veS .Environmental protection and market reverse industry shift speed up
veSChina's API export structure, penicillin, vitamins, heat relief analgesics and other bulk API proportion is too high, in previous years the industry extensive, rapid development, the current competitiveness is obviously weakened, the profit margin is very low, the API industry is facing from the bulk of RAW drugs mainly, to the value-added higher characteristics of API and preparation transformation. The pharmaceutical industry is in a period of speed shifting, it can be said that the new growth point has not yet been formed, the old comparative advantage is being lost. Only through the transformation and upgrading to reduce the impact on the industry, the use of the international division of labor new transfer, to speed up the speed of China's pharmaceutical enterprises, especially the internationalization process speed up.
veS .Industry insiders believe that enterprises should deal with industrial transformation and upgrading from four aspects: First, to continue to vigorously explore the international market, and strive to expand the share, increase the efforts to open up surrounding markets and emerging markets;
veS .Xu Ming believes that stress and urgency will inspire more momentum, so that the industry into a healthier, more sustainable, standardized development track. The adjustment of industrial structure will bring a new round of "shuffle", it is suggested that small micro-enterprises choose new partners, but also can also cooperate with some large groups to become their production units.
veS ."The transformation of big business is constrained by all aspects, it is not possible to upgrade products any time soon, it will be in a very awkward position, and the pressure will be even greater." "The transformation and upgrading of the API industry, both the market's reverse mechanism, but also the new version of GMP and environmental protection and other policy-oriented factors, as well as enterprises based on their own strategic transformation needs, several factors make the transformation and upgrading of API enterprises will be a slow adjustment process," said The Deputy Secretary-General of the Medical Insurance Chamber of Commerce.
veS
Xinhua data in January and February show that China's API exports continued to be depressed since the fourth quarter of 2012, short-term difficult to reverse. The task of industry transformation and upgrading is arduous, and the industry is feeling more and more pressure.
veS .Export growth continued to hover at a low
veS2013, is a rough year for the API industry, many problems are gradually emerging or getting worse during the year. According to data provided by the China Medical and Health Products Import and Export Chamber of Commerce (hereinafter referred to as the "Medical Insurance Chamber of Commerce"), China's exports of API were US$23.6 billion last year, up 2.6% YoY;
veS .In January and February this year, the situation continued last year, export growth rate is still hovering at a low level, export volume and export volume slightly increased, and export volume growth is smaller than the increase in export volume. In January-February, exports of API increased by 5% year-on-year to 1.03 million tons, while exports amounted to US$3.8 billion, up 3.9% YoY. Average unit prices for exports fell by 1.3% year-on-year.
veS .　　Bulk API belongs to the more mature products, the entry threshold is low, the technical and equipment requirements are simple, the production enterprises are very many, the competition is fierce. This kind of product has always been the most advantageous pharmaceutical export varieties in China. "But since the fourth quarter of 2012, exports of API, especially bulk API, have fallen sharply, with more than a dozen of the major API drugs exported in 2013 showing double-digit negative growth." Xu Ming, vice president of the Medical Insurance Chamber of Commerce, told reporters: "The bulk of API has entered the downward channel, in the short term it is difficult to reverse the trend." It's good to expect growth of 1% to 2% for the full year. "
veS in recent years, the export of specialty api, the profit margin of such products is relatively large, less domestic manufacturers. From January and February of this year, the market of specialty api, such as statins, anti-cancer drugs, etc. is good, Cao Gang, director of the Western Pharmaceutical Department of the Medical Insurance Chamber of Commerce, expects the annual growth rate of RAW drugs exports will remain at about 5%-8%.
veS .　　Ranking Merchandise Exports (US$10,000) Growth Export Price (USD/kg)
veS 1 Vitamin E 56,155 -13.32% 14.56
veS 2 Vitamin C 26,842 -2.48% 3.46
veS 3 tetracycline 16,472 -7.40% 24.67
Pine 13,132 19.47% 996.04
veS 5 Lincomycmycin 12,861 5.60% 113.35
veS 6 Coenzyme Q10 8,328 -24.87% 218.86
veS 7 vitamin B6 6,938 -7.59% 22.5
s . Vitamin B1 6,575 -13.10% 18.1
veS 9 Caffeine 6,417 -4.84% 8.4
veS 10 Vitamin B5 6,355 14.89% 7.64
veS multiple reasons caused by the decline of RAW materials exports
S after the previous two years of exports of RAW materials up to double-digit growth, the industry's export growth in the last two years is difficult.
veS .　　Industry analysis, there are mainly the following reasons: from the external market, foreign customers due to financial constraints to reduce inventory and procurement volume, more attention to prices, increased inquiries, large orders, long orders into small single; Even some enterprises lack of integrity, contract awareness is indifferent, and foreign customers to cooperate quickly and quickly, but also affected China's API products in the international market reputation and customer long-term cooperation.
veS .　　In addition, the fluctuation of RMB exchange rate also to a certain extent increases the difficulty of enterprise pricing, affecting enterprises to take orders. Although some companies require sales contracts at current exchange rates or rmb to settle in exchange rates in order to reduce the risk of fluctuations in the renminbi, customers generally do not agree to settle in renminbi for their own benefit.
veS .　　Environmental protection and market reverse industry shift speed up
veS China's API export structure, penicillin, vitamins, heat relief analgesics and other bulk API proportion is too high, in previous years the industry extensive, rapid development, the current competitiveness is obviously weakened, the profit margin is very low, the API industry is facing from the bulk of RAW drugs mainly, to the value-added higher characteristics of API and preparation transformation. The pharmaceutical industry is in a period of speed shifting, it can be said that the new growth point has not yet been formed, the old comparative advantage is being lost. Only through the transformation and upgrading to reduce the impact on the industry, the use of the international division of labor new transfer, to speed up the speed of China's pharmaceutical enterprises, especially the internationalization process speed up.
veS .　　Industry insiders believe that enterprises should deal with industrial transformation and upgrading from four aspects: First, to continue to vigorously explore the international market, and strive to expand the share, increase the efforts to open up surrounding markets and emerging markets;
veS .　　Xu Ming believes that stress and urgency will inspire more momentum, so that the industry into a healthier, more sustainable, standardized development track. The adjustment of industrial structure will bring a new round of "shuffle", it is suggested that small micro-enterprises choose new partners, but also can also cooperate with some large groups to become their production units.
veS.